

Leonidas Stefanis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8889919/publications.pdf>

Version: 2024-02-01

164
papers

10,190
citations

66343

42
h-index

36028

97
g-index

169
all docs

169
docs citations

169
times ranked

13010
citing authors

#	ARTICLE	IF	CITATIONS
1	Impaired Degradation of Mutant $\hat{\pm}$ -Synuclein by Chaperone-Mediated Autophagy. <i>Science</i> , 2004, 305, 1292-1295.	12.6	1,762
2	$\hat{\pm}$ -Synuclein in Parkinson's Disease. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2012, 2, a009399-a009399.	6.2	958
3	Cell-Produced $\hat{\pm}$ -Synuclein Is Secreted in a Calcium-Dependent Manner by Exosomes and Impacts Neuronal Survival. <i>Journal of Neuroscience</i> , 2010, 30, 6838-6851.	3.6	913
4	Wild Type $\hat{\pm}$ -Synuclein Is Degraded by Chaperone-mediated Autophagy and Macroautophagy in Neuronal Cells. <i>Journal of Biological Chemistry</i> , 2008, 283, 23542-23556.	3.4	553
5	Expression of A53T Mutant But Not Wild-Type $\hat{\pm}$ -Synuclein in PC12 Cells Induces Alterations of the Ubiquitin-Dependent Degradation System, Loss of Dopamine Release, and Autophagic Cell Death. <i>Journal of Neuroscience</i> , 2001, 21, 9549-9560.	3.6	540
6	Pathological roles of $\hat{\pm}$ -synuclein in neurological disorders. <i>Lancet Neurology</i> , The, 2011, 10, 1015-1025.	10.2	328
7	Abberant $\hat{\pm}$ -Synuclein Confers Toxicity to Neurons in Part through Inhibition of Chaperone-Mediated Autophagy. <i>PLoS ONE</i> , 2009, 4, e5515.	2.5	304
8	Proteasomal inhibition leads to formation of ubiquitin/ $\hat{\pm}$ -synuclein-immunoreactive inclusions in PC12 cells. <i>Journal of Neurochemistry</i> , 2001, 78, 899-908.	3.9	253
9	Alpha-synuclein and Protein Degradation Systems: a Reciprocal Relationship. <i>Molecular Neurobiology</i> , 2013, 47, 537-551.	4.0	222
10	Autophagy and α -Synuclein: Relevance to Parkinson's Disease and Related Synucleopathies. <i>Movement Disorders</i> , 2016, 31, 178-192.	3.9	216
11	Cell-produced $\hat{\pm}$ -synuclein oligomers are targeted to, and impair, the 26S proteasome. <i>Neurobiology of Aging</i> , 2010, 31, 953-968.	3.1	185
12	Boosting chaperone-mediated autophagy in vivo mitigates $\hat{\pm}$ -synuclein-induced neurodegeneration. <i>Brain</i> , 2013, 136, 2130-2146.	7.6	175
13	Motor and Nonmotor Features of Carriers of the p.A53T Alpha-Synuclein Mutation: A Longitudinal Study. <i>Movement Disorders</i> , 2016, 31, 1226-1230.	3.9	134
14	Mediterranean diet adherence is related to reduced probability of prodromal Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 48-57.	3.9	134
15	Defective synaptic connectivity and axonal neuropathology in a human iPSC-based model of familial Parkinson's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E3679-E3688.	7.1	122
16	Proteasomal Inhibition-Induced Inclusion Formation and Death in Cortical Neurons Require Transcription and Ubiquitination. <i>Molecular and Cellular Neurosciences</i> , 2002, 21, 223-238.	2.2	118
17	How is α -synuclein cleared from the cell?. <i>Journal of Neurochemistry</i> , 2019, 150, 577-590.	3.9	113
18	The protective role of AMP-activated protein kinase in alpha-synuclein neurotoxicity in vitro. <i>Neurobiology of Disease</i> , 2014, 63, 1-11.	4.4	97

#	ARTICLE	IF	CITATIONS
19	Inducible overexpression of wild type α -synuclein in human neuronal cells leads to caspase-dependent non-apoptotic death. <i>Journal of Neurochemistry</i> , 2009, 109, 1348-1362.	3.9	96
20	Neurobiology of α -Synuclein. <i>Molecular Neurobiology</i> , 2004, 30, 001-022.	4.0	95
21	A multi-centre clinico-genetic analysis of the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-associated variants. <i>Journal of Medical Genetics</i> , 2012, 49, 721-726.	3.2	94
22	Impairment of chaperone-mediated autophagy induces dopaminergic neurodegeneration in rats. <i>Autophagy</i> , 2016, 12, 2230-2247.	9.1	87
23	Autophagic pathways in Parkinson disease and related disorders. <i>Expert Reviews in Molecular Medicine</i> , 2011, 13, e8.	3.9	84
24	Synuclein-1 is selectively up-regulated in response to nerve growth factor treatment in PC12 cells. <i>Journal of Neurochemistry</i> , 2001, 76, 1165-1176.	3.9	80
25	Genetics of Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017, 132, 197-231.	2.0	76
26	Modulation of β -glucocerebrosidase increases α -synuclein secretion and exosome release in mouse models of Parkinson's disease. <i>Human Molecular Genetics</i> , 2018, 27, 1696-1710.	2.9	75
27	Alpha-synuclein research: defining strategic moves in the battle against Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2021, 7, 65.	5.3	74
28	Serotonergic pathology and disease burden in the premotor and motor phase of A53T α -synuclein parkinsonism: a cross-sectional study. <i>Lancet Neurology</i> , The, 2019, 18, 748-759.	10.2	70
29	ADCY5-related movement disorders: Frequency, disease course and phenotypic variability in a cohort of paediatric patients. <i>Parkinsonism and Related Disorders</i> , 2017, 41, 37-43.	2.2	67
30	Long Non-coding RNAs Associated With Neurodegeneration-Linked Genes Are Reduced in Parkinson's Disease Patients. <i>Frontiers in Cellular Neuroscience</i> , 2019, 13, 58.	3.7	63
31	Plasma alpha-synuclein levels in patients with Parkinson's disease: a systematic review and meta-analysis. <i>Neurological Sciences</i> , 2019, 40, 929-938.	1.9	59
32	Targeting intracellular and extracellular alpha-synuclein as a therapeutic strategy in Parkinson's disease and other synucleinopathies. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, 421-432.	3.4	58
33	Evidence of an association between the scavenger receptor class B member 2 gene and Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 400-405.	3.9	56
34	Chaperone mediated autophagy in aging: Starve to prosper. <i>Ageing Research Reviews</i> , 2016, 32, 13-21.	10.9	55
35	A Novel SNCA A30G Mutation Causes Familial Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 1624-1633.	3.9	54
36	Lysosomal alterations in peripheral blood mononuclear cells of Parkinson's disease patients. <i>Movement Disorders</i> , 2015, 30, 1830-1834.	3.9	53

#	ARTICLE	IF	CITATIONS
37	Chaperone mediated autophagy to the rescue: A new-fangled target for the treatment of neurodegenerative diseases. <i>Molecular and Cellular Neurosciences</i> , 2015, 66, 29-36.	2.2	53
38	A novel pathway for transcriptional regulation of α -synuclein. <i>FASEB Journal</i> , 2007, 21, 596-607.	0.5	50
39	Progressive striatonigral degeneration in a transgenic mouse model of multiple system atrophy: translational implications for interventional therapies. <i>Acta Neuropathologica Communications</i> , 2018, 6, 2.	5.2	50
40	Functional dissection of the α -synuclein promoter: transcriptional regulation by ZSCAN21 and ZNF219. <i>Journal of Neurochemistry</i> , 2009, 110, 1479-1490.	3.9	49
41	β -Glucocerebrosidase gene mutations in two cohorts of Greek patients with sporadic Parkinson's disease. <i>Molecular Genetics and Metabolism</i> , 2011, 104, 149-152.	1.1	47
42	Loss of β -Glucocerebrosidase Activity Does Not Affect Alpha-Synuclein Levels or Lysosomal Function in Neuronal Cells. <i>PLoS ONE</i> , 2013, 8, e60674.	2.5	47
43	Endogenous oligodendroglial alpha-synuclein and TPPP/p25 α orchestrate alpha-synuclein pathology in experimental multiple system atrophy models. <i>Acta Neuropathologica</i> , 2019, 138, 415-441.	7.7	45
44	Lack of p53 delays apoptosis, but increases ubiquitinated inclusions, in proteasomal inhibitor-treated cultured cortical neurons. <i>Molecular and Cellular Neurosciences</i> , 2003, 24, 430-441.	2.2	43
45	Circulating Brain-Enriched MicroRNAs for Detection and Discrimination of Idiopathic and Genetic Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 457-467.	3.9	43
46	Regulation of α -synuclein by bFGF in cultured ventral midbrain dopaminergic neurons. <i>Journal of Neurochemistry</i> , 2003, 84, 803-813.	3.9	39
47	Differentially Expressed Circular α -RNAs in Peripheral Blood Mononuclear Cells of Patients with Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 1170-1179.	3.9	38
48	Validation of differentially expressed brain-enriched microRNAs in the plasma of PD patients. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 1594-1607.	3.7	36
49	Alpha-synuclein dimerization in erythrocytes of patients with genetic and non-genetic forms of Parkinson's Disease. <i>Neuroscience Letters</i> , 2018, 672, 145-149.	2.1	35
50	Selective neuroprotective effects of the S18Y polymorphic variant of UCH-L1 in the dopaminergic system. <i>Human Molecular Genetics</i> , 2012, 21, 874-889.	2.9	34
51	Salivary alpha-synuclein as a biomarker for Parkinson's disease: a systematic review. <i>Journal of Neural Transmission</i> , 2019, 126, 1373-1382.	2.8	34
52	Higher probability of prodromal Parkinson disease is related to lower cognitive performance. <i>Neurology</i> , 2019, 92, e2261-e2272.	1.1	34
53	Reduced serum immunoglobulin G concentrations in multiple sclerosis: prevalence and association with disease-modifying therapy and disease course. <i>Therapeutic Advances in Neurological Disorders</i> , 2019, 12, 175628641987834.	3.5	31
54	Selective cognitive impairment and hyposmia in p.A53T α -SNCA PD vs typical PD. <i>Neurology</i> , 2018, 90, e864-e869.	1.1	28

#	ARTICLE	IF	CITATIONS
55	Frontotemporal dementia as the presenting phenotype of p.A53T mutation carriers in the alpha-synuclein gene. <i>Parkinsonism and Related Disorders</i> , 2017, 35, 82-87.	2.2	27
56	Organochlorine pesticide levels in Greek patients with Parkinson's disease. <i>Toxicology Reports</i> , 2020, 7, 596-601.	3.3	27
57	In silico modeling of the effects of alpha-synuclein oligomerization on dopaminergic neuronal homeostasis. <i>BMC Systems Biology</i> , 2014, 8, 54.	3.0	26
58	Corticobasal degeneration and corticobasal syndrome: A review. <i>Clinical Parkinsonism & Related Disorders</i> , 2019, 1, 66-71.	0.9	26
59	Increased dimerization of alpha-synuclein in erythrocytes in Gaucher disease and aging. <i>Neuroscience Letters</i> , 2012, 528, 205-209.	2.1	24
60	Isolated delusional syndrome in Parkinson's Disease. <i>Parkinsonism and Related Disorders</i> , 2010, 16, 550-552.	2.2	23
61	Distinct alpha-synuclein species induced by seeding are selectively cleared by the Lysosome or the Proteasome in neuronally differentiated SH-SY5Y cells. <i>Journal of Neurochemistry</i> , 2021, 156, 880-896.	3.9	22
62	The relationship between environmental factors and different Parkinson's disease subtypes in Greece: Data analysis of the Hellenic Biobank of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 67, 105-112.	2.2	21
63	Autophagy dysfunction in peripheral blood mononuclear cells of Parkinson's disease patients. <i>Neuroscience Letters</i> , 2019, 704, 112-115.	2.1	21
64	Mendelian Randomisation Study of Smoking, Alcohol, and Coffee Drinking in Relation to Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2022, 12, 267-282.	2.8	21
65	Neuropsychiatric symptoms and α -Synuclein profile of patients with Parkinson's disease dementia, dementia with Lewy bodies and Alzheimer's disease. <i>Journal of Neurology</i> , 2018, 265, 2295-2301.	3.6	20
66	Age-dependent variation of female preponderance across different phenotypes of multiple sclerosis: A retrospective cross-sectional study. <i>CNS Neuroscience and Therapeutics</i> , 2019, 25, 527-531.	3.9	19
67	Medical cannabis as an alternative therapeutics for Parkinson's disease: Systematic review. <i>Complementary Therapies in Clinical Practice</i> , 2020, 39, 101154.	1.7	19
68	Complex Effects of the ZSCAN21 Transcription Factor on Transcriptional Regulation of α -Synuclein in Primary Neuronal Cultures and in Vivo. <i>Journal of Biological Chemistry</i> , 2016, 291, 8756-8772.	3.4	18
69	Clinical rating scale for pantothenate kinase-associated neurodegeneration: A pilot study. <i>Movement Disorders</i> , 2017, 32, 1620-1630.	3.9	18
70	Phenotypic Characteristics in GBA-Associated Parkinson's Disease: A Study in a Greek Population. <i>Journal of Parkinson's Disease</i> , 2018, 8, 101-105.	2.8	18
71	Midbrain morphology in idiopathic normal pressure hydrocephalus: A progressive supranuclear palsy mimic. <i>Acta Neurologica Scandinavica</i> , 2020, 141, 328-334.	2.1	18
72	Resistance of naturally secreted α -synuclein to proteolysis. <i>FASEB Journal</i> , 2014, 28, 3146-3158.	0.5	18

#	ARTICLE	IF	CITATIONS
73	Motor function and the probability of prodromal Parkinson's disease in older adults. <i>Movement Disorders</i> , 2019, 34, 1345-1353.	3.9	16
74	Frontotemporal dementia spectrum: first genetic screen in a Greek cohort. <i>Neurobiology of Aging</i> , 2019, 75, 224.e1-224.e8.	3.1	16
75	Frailty and Prodromal Parkinson's Disease: Results From the HELIAD Study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021, 76, 622-629.	3.6	16
76	Activation of FADD-Dependent Neuronal Death Pathways as a Predictor of Pathogenicity for LRRK2 Mutations. <i>PLoS ONE</i> , 2016, 11, e0166053.	2.5	16
77	A Prospective Validation of the Updated Movement Disorders Society Research Criteria for Prodromal Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 1802-1809.	3.9	15
78	Recurrent Fulminant Tumefactive Demyelination With Marburg-Like Features and Atypical Presentation: Therapeutic Dilemmas and Review of Literature. <i>Frontiers in Neurology</i> , 2020, 11, 536.	2.4	15
79	Endogenous Levels of Alpha-Synuclein Modulate Seeding and Aggregation in Cultured Cells. <i>Molecular Neurobiology</i> , 2022, 59, 1273-1284.	4.0	15
80	Dairy Intake and Parkinson's Disease: A Mendelian Randomization Study. <i>Movement Disorders</i> , 2022, 37, 857-864.	3.9	15
81	Regulation of α -synuclein expression in cultured cortical neurons. <i>Journal of Neurochemistry</i> , 2011, 117, 275-285.	3.9	14
82	Cerebrospinal Fluid α -Synuclein Species in Cognitive and Movements Disorders. <i>Brain Sciences</i> , 2021, 11, 119.	2.3	14
83	α -Synuclein dimerization in erythrocytes of Gaucher disease patients: correlation with lipid abnormalities and oxidative stress. <i>Neuroscience Letters</i> , 2016, 613, 1-5.	2.1	13
84	Identification of a prospective early motor progression cluster of Parkinson's disease: Data from the PPMI study. <i>Journal of the Neurological Sciences</i> , 2018, 387, 103-108.	0.6	13
85	Levodopa-induced skin disorders in patients with Parkinson disease: a systematic literature review approach. <i>Acta Neurologica Belgica</i> , 2019, 119, 325-336.	1.1	13
86	High discriminatory ability of peripheral and CFSF biomarkers in Lewy body diseases. <i>Journal of Neural Transmission</i> , 2020, 127, 311-322.	2.8	13
87	Cerebrospinal fluid biomarker profiling in corticobasal degeneration: Application of the AT(N) and other classification systems. <i>Parkinsonism and Related Disorders</i> , 2021, 82, 44-49.	2.2	13
88	Decreased levels of α -synuclein in cerebrospinal fluid of patients with clinically isolated syndrome and multiple sclerosis. <i>Journal of Neurochemistry</i> , 2015, 134, 748-755.	3.9	12
89	Peripheral α -synuclein levels in patients with genetic and non-genetic forms of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2020, 73, 35-40.	2.2	12
90	Serum Uric Acid Level as a Biomarker in Idiopathic and Genetic (p.A53T Alpha-Synuclein Carriers) Parkinson's Disease: Data from the PPMI Study. <i>Journal of Parkinson's Disease</i> , 2020, 10, 481-487.	2.8	12

#	ARTICLE	IF	CITATIONS
91	Nurr1 repression mediates cardinal features of Parkinson's disease in α -synuclein transgenic mice. Human Molecular Genetics, 2021, 30, 1469-1483.	2.9	12
92	Distinct profiles of LRRK2 activation and Rab GTPase phosphorylation in clinical samples from different PD cohorts. Npj Parkinson's Disease, 2022, 8, .	5.3	12
93	Severe dysphagia as the presenting symptom of Wernicke-Korsakoff syndrome in a non-alcoholic man. Neurological Sciences, 2008, 29, 45-46.	1.9	11
94	Impairment of chaperone-mediated autophagy affects neuronal homeostasis through altered expression of DJ-1 and CRMP-2 proteins. Molecular and Cellular Neurosciences, 2019, 95, 1-12.	2.2	11
95	Psychosis-Like Behavior and Hyperdopaminergic Dysregulation in Human α -Synuclein BAC Transgenic Rats. Movement Disorders, 2021, 36, 716-728.	3.9	11
96	Biallelic RFC1 pentanucleotide repeat expansions in Greek patients with late-onset ataxia. Clinical Genetics, 2021, 100, 90-94.	2.0	11
97	Can We Treat Neurodegenerative Proteinopathies by Enhancing Protein Degradation?. Movement Disorders, 2022, 37, 1346-1359.	3.9	11
98	The different faces of the p. A53T alpha-synuclein mutation: A screening of Greek patients with parkinsonism and/or dementia. Neuroscience Letters, 2018, 672, 136-139.	2.1	10
99	MOG antibody-associated demyelinating disease mimicking typical multiple sclerosis: A case for expanding anti-MOG testing?. Multiple Sclerosis and Related Disorders, 2019, 33, 67-69.	2.0	10
100	Autophagy mediates the clearance of oligodendroglial SNCA/alpha-synuclein and TPPP/p25A in multiple system atrophy models. Autophagy, 2022, 18, 2104-2133.	9.1	10
101	Duration of paroxysmal atrial fibrillation in cryptogenic stroke is not associated with stroke severity and early outcomes. Journal of the Neurological Sciences, 2017, 376, 191-195.	0.6	9
102	^{123}I -FP-CIT SPECT [(123) ^{123}I -2-carbomethoxy-3-(4-iodophenyl)-N-(3-fluoropropyl) nortropane single photon emission computed tomography] Imaging in a p.A53T α -synuclein Parkinson's disease cohort versus Parkinson's disease. Movement Disorders, 2018, 33, 1734-1739.	3.9	9
103	Clinical, neuropsychological and imaging characteristics of Alzheimer's disease patients presenting as corticobasal syndrome. Journal of the Neurological Sciences, 2019, 398, 142-147.	0.6	9
104	Clinico-radiologic features and therapeutic strategies in tumefactive demyelination: a retrospective analysis of 50 consecutive cases. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110065.	3.5	9
105	Expanding the Spectrum of AP5Z1-Related Hereditary Spastic Paraplegia (HSP-SPG48): A Multicenter Study on a Rare Disease. Movement Disorders, 2021, 36, 1034-1038.	3.9	9
106	Serum uric acid level as a putative biomarker in Parkinson's disease patients carrying GBA1 mutations: 2-Year data from the PPMI study. Parkinsonism and Related Disorders, 2021, 84, 1-4.	2.2	9
107	Immunopathology of Tumefactive Demyelinating Lesions-From Idiopathic to Drug-Related Cases. Frontiers in Neurology, 2022, 13, 868525.	2.4	9
108	Potential Utility of Neurosonology in Paroxysmal Atrial Fibrillation Detection in Patients with Cryptogenic Stroke. Journal of Clinical Medicine, 2019, 8, 2002.	2.4	8

#	ARTICLE	IF	CITATIONS
109	Recurrent myelitis and asymptomatic hypophysitis in IgG4-related disease: case-based review. <i>Rheumatology International</i> , 2020, 40, 337-343.	3.0	8
110	HLA-DPB1*03 as Risk Allele and HLA-DPB1*04 as Protective Allele for Both Early- and Adult-Onset Multiple Sclerosis in a Hellenic Cohort. <i>Brain Sciences</i> , 2020, 10, 374.	2.3	8
111	Apathy: An underestimated feature in GBA and LRRK2 non-manifesting mutation carriers. <i>Parkinsonism and Related Disorders</i> , 2021, 91, 1-8.	2.2	8
112	Î±-Synuclein Induces the GSK-3-Mediated Phosphorylation and Degradation of NURR1 and Loss of Dopaminergic Hallmarks. <i>Molecular Neurobiology</i> , 2021, 58, 6697-6711.	4.0	8
113	Parkinsonism and dementia. <i>Journal of the Neurological Sciences</i> , 2022, 433, 120015.	0.6	8
114	High content screening and proteomic analysis identify a kinase inhibitor that rescues pathological phenotypes in a patient-derived model of Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2022, 8, 15.	5.3	8
115	Evaluation of the interaction between LRRK2 and PARK16 loci in determining risk of Parkinson's disease: analysis of a large multicenter study. <i>Neurobiology of Aging</i> , 2017, 49, 217.e1-217.e4.	3.1	7
116	Three new case reports of Arteriovenous malformation-related Amyotrophic Lateral Sclerosis. <i>Journal of the Neurological Sciences</i> , 2018, 393, 58-62.	0.6	7
117	Autoimmune hemolytic anemia, demyelinating relapse, and AQP1 antibodies after alemtuzumab infusion. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2020, 7, e711.	6.0	7
118	Elevated Serum Î±-Synuclein Levels in Huntington's Disease Patients. <i>Neuroscience</i> , 2020, 431, 34-39.	2.3	7
119	Driving and Alzheimer's dementia or mild cognitive impairment: a systematic review of the existing guidelines emphasizing on the neurologist's role. <i>Neurological Sciences</i> , 2021, 42, 4953-4963.	1.9	7
120	HLA-DRB1 differences in allelic distribution between familial and sporadic multiple sclerosis in a Hellenic cohort. <i>Postgraduate Medicine</i> , 2019, 131, 490-495.	2.0	6
121	HLA-DRB1 allele impact on pediatric multiple sclerosis in a Hellenic cohort. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2020, 6, 205521732090804.	1.0	6
122	Paraneoplastic basal ganglia encephalitis associated with anti-CV2/CRMP-5 and anti-Yo antibodies in a patient with non-small-cell lung cancer. <i>Neurological Sciences</i> , 2020, 41, 2649-2651.	1.9	6
123	REM sleep behavior disorder and other sleep abnormalities in p. A53T SNCA mutation carriers. <i>Sleep</i> , 2021, 44, .	1.1	6
124	Childhood-Onset Chorea Caused by a Recurrent De Novo <i>DRD2</i> Variant. <i>Movement Disorders</i> , 2021, 36, 1472-1473.	3.9	6
125	Fingolimod as a first- or second-line treatment in a mini-series of young Hellenic patients with adolescent-onset multiple sclerosis: focus on immunological data. <i>Neurological Sciences</i> , 2022, 43, 2641-2649.	1.9	6
126	Dietary Inflammatory Index score and prodromal Parkinson's disease incidence: The HELIAD study. <i>Journal of Nutritional Biochemistry</i> , 2022, 105, 108994.	4.2	6

#	ARTICLE	IF	CITATIONS
127	Magnetic resonance imaging reveals Creutzfeldt-Jakob disease in a patient with apparent dementia with Lewy bodies. <i>Journal of the Neurological Sciences</i> , 2014, 340, 130-132.	0.6	5
128	A homozygous GDAP2 loss-of-function variant in a patient with adult-onset cerebellar ataxia. <i>Brain</i> , 2020, 143, e49-e49.	7.6	5
129	DaTSCAN (123I-FP-CIT SPECT) imaging in early versus mid and late onset Parkinson's disease: Longitudinal data from the PPMI study. <i>Parkinsonism and Related Disorders</i> , 2020, 77, 36-42.	2.2	5
130	Late life psychotic features in prodromal Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2021, 86, 67-73.	2.2	5
131	IgG4-related autoimmune manifestations in Alemtuzumab-treated multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , 2021, 361, 577759.	2.3	5
132	Cortical involvement and leptomeningeal inflammation in myelin oligodendrocyte glycoprotein antibody disease: A three-dimensional fluid-attenuated inversion recovery MRI study. <i>Multiple Sclerosis Journal</i> , 2022, 28, 718-729.	3.0	4
133	Dopamine transporter SPECT imaging in corticobasal syndrome: A peak into the underlying pathology?. <i>Acta Neurologica Scandinavica</i> , 2022, 145, 762-769.	2.1	4
134	The Interaction between <i>HLA-DRB1</i> and Smoking in Parkinson's Disease Revisited. <i>Movement Disorders</i> , 2022, 37, 1929-1937.	3.9	4
135	Dopamine agonists and delusional jealousy in Parkinson's disease: A cross-sectional prevalence study. <i>Movement Disorders</i> , 2013, 28, 689-689.	3.9	3
136	Neuroimaging findings in Hunter disease. <i>Journal of the Neurological Sciences</i> , 2014, 342, 200-201.	0.6	3
137	Serum Uric Acid in LRRK2 Related Parkinson's Disease: Longitudinal Data from the PPMI Study. <i>Journal of Parkinson's Disease</i> , 2021, 11, 633-640.	2.8	3
138	Variant transthyretin amyloidosis (ATTRv) polyneuropathy in Greece: a broad overview with a focus on non-endemic unexplored regions of the country. <i>Neuromuscular Disorders</i> , 2021, 31, 1251-1258.	0.6	3
139	Effects of a structured dance program in Parkinson's disease. A Greek pilot study. <i>Complementary Therapies in Clinical Practice</i> , 2022, 46, 101528.	1.7	3
140	Natalizumab therapy in patients with pediatric-onset multiple sclerosis in Greece: clinical and immunological insights of time-long administration and future directions—a single-center retrospective observational study. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2022, 395, 933-943.	3.0	3
141	Lipid level alteration in human and cellular models of alpha synuclein mutations. <i>Npj Parkinson's Disease</i> , 2022, 8, 52.	5.3	3
142	Callosal Angle Sub-Score of the Radscale in Patients with Idiopathic Normal Pressure Hydrocephalus Is Associated with Positive Tap Test Response. <i>Journal of Clinical Medicine</i> , 2022, 11, 2898.	2.4	3
143	Resolution of unilateral obstructive hydrocephalus complicating expanding thrombosed basilar apex aneurysm after anticoagulation treatment. <i>Journal of the Neurological Sciences</i> , 2014, 341, 179-181.	0.6	2
144	Analysis of a founder mutation in the <i>TH</i> gene in a cohort of greek patients with Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 1753-1754.	3.9	2

#	ARTICLE	IF	CITATIONS
145	Quantifying apraxia and ophthalmokinetic abnormalities in patients with atypical Parkinsonism: A new way to differential diagnosis?. Parkinsonism and Related Disorders, 2019, 61, 39-44.	2.2	2
146	Area postrema involvement in chronic lymphocytic inflammation with pontine perivascular enhancement. Neurological Sciences, 2021, 42, 361-364.	1.9	2
147	CSF and Circulating NfL as Biomarkers for the Discrimination of Parkinson Disease From Atypical Parkinsonian Syndromes. Neurology: Clinical Practice, 2021, 11, e867-e875.	1.6	2
148	<scp><i>HINT1</i></scp>-related neuropathy in Greek patients with <scp>Charcotâ€Marieâ€Tooth</scp> disease. Journal of the Peripheral Nervous System, 2021, 26, 444-448.	3.1	2
149	Co-occurrence between hereditary angioedema and multiple sclerosis: Therapeutic management of both diseases with fingolimod. Clinical Neurology and Neurosurgery, 2022, 216, 107222.	1.4	2
150	Brain Arteriovenous Malformation and Amyotrophic Lateral Sclerosis: a Review Based on Published Cases. SN Comprehensive Clinical Medicine, 2020, 2, 392-396.	0.6	1
151	Preserved eye movements in adults with spinal muscular atrophy. Muscle and Nerve, 2021, 63, 765-769.	2.2	1
152	The â€œhypointense substantia nigraâ€sign. A novel MRI marker of progressive supranuclear palsy. Journal of the Neurological Sciences, 2021, 421, 117286.	0.6	1
153	Odor Identification Testing Can Assist in the Clinical Distinction Between Psychiatric Disorders and Neurological/Neurodegenerative Disorders. Alzheimer Disease and Associated Disorders, 2021, 35, 244-249.	1.3	1
154	The factors associated with the presence of psychotic symptoms in the HELIAD Greek community study of older adults. Aging and Mental Health, 2021, , 1-10.	2.8	1
155	A double-hit in vivo model of GBA viral microRNA-mediated downregulation and human alpha-synuclein overexpression demonstrates nigrostriatal degeneration. Neurobiology of Disease, 2022, 163, 105612.	4.4	1
156	Lupus-like disease and progressive multifocal leukoencephalopathy following etanercept treatment: just a coincidence?. Clinical and Experimental Rheumatology, 2022, 40, 671-672.	0.8	1
157	Teaching Neuro <i>Images</i> : MRI-visible Virchow-Robin perivascular spaces in cerebral small-vessel disease. Neurology, 2014, 83, e119-20.	1.1	0
158	Response to correspondence: Testing for myelin oligodendrocyte glycoprotein antibody (MOG-IgG) in typical MS. Multiple Sclerosis and Related Disorders, 2019, 35, 156-157.	2.0	0
159	Ocular flutter as the cardinal feature of anti-GM2 rhombencephalitis. Neurological Sciences, 2021, 42, 3003-3005.	1.9	0
160	Reply to: â€œÎ±â€Synuclein (<scp><i>SNCA</i></scp>) <scp>A30G</scp> Mutation as a Cause of a Complex Phenotype Without Parkinsonismâ€ Movement Disorders, 2021, 36, 2212-2213.	3.9	0
161	Effect of Apolipoprotein E4 on the Driving Behavior of Patients with Amnesic Mild Cognitive Impairment or Mild Alzheimerâ€™s Disease Dementia. Journal of Alzheimer's Disease, 2021, 84, 1005-1014.	2.6	0
162	Alpha-synuclein gene and Parkinson's disease. , 2020, , 19-34.		0

#	ARTICLE	IF	CITATIONS
163	Asymptomatic carriers of the p.A53T SNCA mutation: Data from the PPMI study. Parkinsonism and Related Disorders, 2022, 98, 72-74.	2.2	0
164	Lupus-like disease and progressive multifocal leukoencephalopathy following etanercept treatment: just a coincidence?. Clinical and Experimental Rheumatology, 2021, , .	0.8	0